Evaxion A/S (EVAX)
| Market Cap | 25.44M +44.9% |
| Revenue (ttm) | 7.53M +128.6% |
| Net Income | -9.76M |
| EPS | -1.37 |
| Shares Out | 8.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,455 |
| Open | 3.380 |
| Previous Close | 3.320 |
| Day's Range | 3.050 - 3.405 |
| 52-Week Range | 2.110 - 12.150 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | 11.25 (+268.85%) |
| Earnings Date | May 7, 2026 |
About EVAX
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin... [Read more]
Financial Performance
In 2025, Evaxion's revenue was $7.53 million, an increase of 125.12% compared to the previous year's $3.34 million. Losses were -$7.71 million, -27.07% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price target is $11.25, which is an increase of 268.85% from the latest price.
News
Evaxion receives Prix Galien UK Award for Best digital health solution
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded th...
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new precl...
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the fu...
Evaxion Earnings Call Transcript: Q1 2026
Q1 2026 saw strong clinical and immunogenicity data for EVX-01, expanded AI-Immunology applications, and disciplined financial management with a cash runway into H2 2027. Leadership was strengthened and multiple partnership discussions are ongoing.
Evaxion Earnings release: Q1 2026
Evaxion released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Evaxion Slides: Q1 2026
Evaxion has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Evaxion announces business update and first quarter 2026 financial results
COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business upd...
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a busine...
Evaxion Biotech management to meet with Maxim
Meeting to be held on April 30 hosted by Maxim.
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø...
Evaxion says EVX-01 demonstrates 86% vaccine target precision in trial
Evaxion announces new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego...
Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data...
Evaxion Biotech announces new data to be presented at AACR meeting
Evaxion A/S announces new data demonstrating the platform’s ability to also potentially develop vaccines for glioblastoma. The data, which will be presented at the AACR Annual Meeting in San Diego,…
Evaxion concludes Annual General Meeting
COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual Ge...
Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial
Evaxion (EVAX) has completed the one-year extension of its phase 2 trial with personalized cancer vaccine EVX-01 with the last patient having now had last physician visit. Patients in the…
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has in collaborati...
Notice to convene Evaxion's Annual General Meeting
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its...
Evaxion Biotech assumed with a Buy at JonesResearch
JonesResearch assumed coverage of Evaxion Biotech (EVAX) with a Buy rating and $10 price target The firm says the company uses its AI-driven platform to design novel oncology and infectious…
Evaxion Biotech price target lowered to $9 from $11 at Lake Street
Lake Street lowered the firm’s price target on Evaxion Biotech (EVAX) to $9 from $11 and keeps a Buy rating on the shares. The firm updated the outlook for potential…
Evaxion Earnings Call Transcript: Q4 2025
Strong 2025 progress included a key MSD in-licensing, Gates Foundation collaboration, and robust clinical and preclinical data across oncology and infectious diseases. Financial stability improved with a $23M year-end cash position and a runway into H2 2027.
Evaxion Annual report: Q4 2025
Evaxion has published its Q4 2025 annual report on March 6, 2026.
Evaxion Earnings release: Q4 2025
Evaxion released its Q4 2025 earnings on March 6, 2026, summarizing the period's financial results.
Evaxion Annual report: Q4 2025
Evaxion has published its Q4 2025 annual report on March 6, 2026.
Evaxion Slides: Q4 2025
Evaxion has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 6, 2026.
Evaxion Biotech reports Q4 EPS (2c) vs. (21c) last year
Reports Q4 revenue $0 vs. $122,000 last year. “We made tremendous progress in 2025 across all aspects of our business and achieved several vital points of validation of both our…